Table 1.
Patient characteristics and KCNJ3 expression levels as determined by different methods
| Clinicopathological patient characteristics | Results of KCNJ3 expression | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| # | AAD | Grade | pT | LN | pM | ER | PR | Microarray | IHC | RNA ISH |
| 01 | 78 | 2 | 2 | 3/20 | − | + | + | 11.407 | 3 | 33.33 |
| 02 | 60 | 2 | 2 | 5/20 | − | + | + | 9.417 | 3 | 10.11 |
| 03 | 56 | 2 | 2 | 3/23 | − | + | + | 9.393 | 3 | 9.01 |
| 04 | 71 | 2 | 2 | 0/29 | − | + | + | 9.109 | 2 | 2.69 |
| 05 | 68 | 3 | 2 | 0/18 | − | + | − | 8.917 | 1 | 0.33 |
| 06 | 68 | 2 | 1 | 11/18 | − | + | + | 8.239 | 3 | 1.28 |
| 07 | 43 | 2 | 3 | 2/8 | − | + | − | 8.207 | 1 | 2.10 |
| 08 | 50 | 1 | 4 | 0/11 | − | + | − | 8.061 | 3 | 0.28 |
| 09 | 70 | 3 | 2 | 0/17 | + | + | + | 8.042 | 2 | 1.53 |
| 10 | 63 | 2 | 2 | 0/14 | − | + | − | 7.919 | 0 | 0.16 |
| 11 | 62 | 3 | 2 | 9/27 | + | + | + | 7.205 | 1 | 0.07 |
| 12 | 50 | 1 | 1 | 3/16 | − | + | + | 7.174 | 1 | 0.28 |
| 13 | 63 | 2 | 1 | 0/0 | + | + | + | 6.918 | 1 | 1.26 |
| 14 | 53 | 2 | 4 | 16/19 | − | + | + | 6.740 | 2 | 0.07 |
| 15 | 70 | 2 | 2 | 3/14 | − | + | − | 5.656 | 0 | 0.07 |
#, patient sample number; −, negative; +, positive; AAD, age at diagnosis; ER, oestrogen receptor; IHC, immunohistochemical score of KCNJ3 protein expression; LN, lymph nodes (positive/total examined); Microarray, log2 intensities of KCNJ3 expression; pM, distant metastasis status; PR, progesterone receptor; pT, tumour size staging; RNA ISH, KCNJ3 RNA in situ hybridisation results as spots/cell.